Multiplikator Forward P/S Twist Bioscience (TWST)
The forward P/S metric demonstrates the market perception of Twist Bioscience (TWST), whose leadership in silicon-based DNA synthesis is confirmed by the value of 17.40. Stability is ensured by diversification into the agricultural sector and data storage, while the growth strategy relies on partnerships with Big Pharma for antibody development without pursuing mergers.
Twist Bioscience Corp - rincian analitis lan metrik utama (TWST)
- rega pasar lan target rega analis:
- rincian kapitalisasi pasar:
- statistik nilai buku emiten:
- data tingkat utang lan likuiditas finansial:
Utang marang Ekuitas Twist Bioscience|TWST - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang modal Twist Bioscience|TWST - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Twist Bioscience Corp|TWST - Utang jangka dawa|Kewajiban jangka cendhak perusahaan Twist Bioscience|Indikator likuiditas cepet twistbioscience.com
- rincian asil keuangan lan kelipatan valuasi:
TWST - Penghasilan resik|Bathi sing dikarepake Twist Bioscience|TWST - Periode bali modal bisnis|Prakiraan rega marang bathi Twist Bio|TWST - Rasio nilai perusahaan marang wutah bathi|Pangali EV/EBITDA Twist Bioscience Corp|TWST - Bathi operasional sadurunge amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Twist Bioscience|TWST - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan twistbioscience.com|TWST - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Twist Bioscience
- indikator volume dodolan lan pendapatan:
Analisis kabeh metrik perusahaan:Twist Bioscience, Inc. TWST
Twist Bioscience (TWST) scales DNA synthesis on its own semiconductor platforms with moderate dependence on raw material suppliers. By analyzing the business's forward P/S, an investor assesses the company's market value relative to expected future sales volume. This ratio identifies whether an asset is overvalued or undervalued by correlating the current share price with projected revenue. Monitoring the indicator's extremes allows institutional players to effectively protect capital from volatility.
Analisis pesaing
Rasio rega marang prakiraan pendapatan Tempus AI, Inc. TEM|Rasio kapitalisasi marang dodolan sing dikarepake Qiagen NV (QGEN)|Ionis Pharma - Multiplikator Forward P/S|Repligen Inc. (RGEN) - Multiplikator forward rega marang pendapatan|RNA: Multiplikator Forward P/S|CRSP - Rasio kapitalisasi marang dodolan sing dikarepake|WGS (GeneDx) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Ultragenyx Pharmaceutical Inc. RARE|Rasio rega marang prakiraan pendapatan Beam Therapeutics Corp (BEAM)|Sarepta Corp - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S TXG (10x Genomics, Inc.)|NTLA - Multiplikator forward rega marang pendapatan|Stoke Therapeutics, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep BioLife Solutions Inc|WVE (Wave Life Sciences Corp) - Multiplikator forward rega marang pendapatan|MAZE: Rasio rega marang pendapatan sing dikarepake|Multiplikator forward rega marang pendapatan SION|Multiplikator forward rega marang pendapatan primemedicine.com (PRME)|Rasio rega marang prakiraan pendapatan Taysha Gene Therapies, Inc. (TSHA)|Rasio kapitalisasi marang dodolan sing dikarepake uniQure NV|MeiraGTx PLC - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake RGNX (REGENXBIO Corp)|Solid Biosciences Inc. - Multiplikator Forward P/S|OCGN (ocugen.com) - Kapitalisasi marang prakiraan pendapatan|PacBio (PACB) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan BNTC|DSGN (Design Pharma) - Multiplikator Forward P/S|Multiplikator Forward P/S Rocket Corp|Multiplikator forward rega marang pendapatan FDMT (4D Molecular Therapeutics)|Rasio rega marang pendapatan sing dikarepake LXEO|Korro Bio - Multiplikator forward rega marang pendapatan|EDIT - Multiplikator forward rega marang pendapatan|Silence Therapeutics Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake ProQR Therapeutics N.V. PRQR|codexis.com (CDXS) - Rasio rega marang prakiraan pendapatan|SGMO - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan NAUT|MGX (Metagenomi Inc.) - Rasio rega marang pendapatan sing dikarepake|Multiplikator forward rega marang pendapatan DTIL (Precision BioSciences, Inc.)|GBIO (generationbio.com) - Rega forward marang dodolan|Multiplikator Forward P/S BOLD (Boundless Bio, Inc.)|Exicure Inc. - Rasio rega marang prakiraan pendapatan|Celsion Corporation - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Phio Pharmaceuticals PHIO|mustangbio.com (MBIO) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep TransCode Therapeutics, Inc. (RNAZ)|Rasio rega marang prakiraan pendapatan Bionano Genomics Inc.|adnas.com (APDN) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S BLUE|Multiplikator forward rega marang pendapatan immunoprecise.com IPA|Multiplikator Forward P/S OMGA (Omega)|Rasio kapitalisasi marang dodolan sing dikarepake Singular Genomics Corp (OMIC)|Regulus Therapeutics - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep syros.com|Telesis Bio (TBIO) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan TCON|UBX (Unity Bio) - Multiplikator Forward P/S
